Research progress on the relationship between DNA damage repair genes and liver cancer

Abstract

Di Weihua, Zhao Xuemei. Research progress on the relationship between DNA damage repair genes and liver cancer[J]. Journal of International Oncology, 2022, 49(10): 635-638.

References30

[1]	Gillman R, Lopes Floro K, Wankell M, et al. The role of DNA damage and repair in liver cancer[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875(1): 188493. DOI: 10.1016/j.bbcan.2020.188493. doi:10.1016/j.bbcan.2020.188493
[2]	Lin J, Shi J, Guo H, et al. Alterations in DNA damage repair genes in primary liver cancer[J]. Clin Cancer Res, 2019, 25(15): 4701-4711. DOI: 10.1158/1078-0432.CCR-19-0127. doi:10.1158/1078-0432.CCR-19-0127pmid:31068370
[3]	Xiong Y, Zhang Q, Ye J, et al. Associations between three XRCC1 polymorphisms and hepatocellular carcinoma risk: a meta-analysis of case-control studies[J]. PLoS One, 2018, 13(11): e0206853. DOI: 10.1371/journal.pone.0206853. doi:10.1371/journal.pone.0206853
[4]	Kumar N, Raja S, Van Houten B. The involvement of nucleotide excision repair proteins in the removal of oxidative DNA damage[J]. Nucleic Acids Res, 2020, 48(20): 11227-11243. DOI: 10.1093/nar/gkaa777. doi:10.1093/nar/gkaa777pmid:33010169
[5]	Zhuo Z, Miao L, Hua W, et al. Genetic variations in nucleotide excision repair pathway genes and hepatoblastoma susceptibility[J]. Int J Cancer, 2021, 149(9): 1649-1658. DOI: 10.1002/ijc.33722. doi:10.1002/ijc.33722
[6]	Saha J, Bae J, Wang SY, et al. Ablating putative Ku70 phosphorylation sites results in defective DNA damage repair and spontaneous induction of hepatocellular carcinoma[J]. Nucleic Acids Res, 2021, 49(17): 9836-9850. DOI: 10.1093/nar/gkab743. doi:10.1093/nar/gkab743pmid:34428289
[7]	Yue X, Bai C, Xie D, et al. DNA-PKcs: a multi-faceted player in DNA damage response[J]. Front Genet, 2020, 11: 607428. DOI: 10.3389/fgene.2020.607428. doi:10.3389/fgene.2020.607428
[8]	Pannunzio NR, Watanabe G, Lieber MR. Nonhomologous DNA end-joining for repair of DNA double-strand breaks[J]. J Biol Chem, 2018, 293(27): 10512-10523. DOI: 10.1074/jbc.TM117.000374. doi:10.1074/jbc.TM117.000374pmid:29247009
[9]	Ma M, Rodriguez A, Sugimoto K. Activation of ATR-related protein kinase upon DNA damage recognition[J]. Curr Genet, 2020, 66(2): 327-333. DOI: 10.1007/s00294-019-01039-w. doi:10.1007/s00294-019-01039-wpmid:31624858
[10]	Ge C, Vilfranc CL, Che L, et al. The BRUCE-ATR signaling axis is required for accurate DNA replication and suppression of liver cancer development[J]. Hepatology, 2019, 69(6): 2608-2622. DOI: 10.1002/hep.30529. doi:10.1002/hep.30529pmid:30693543
[11]	朱柯亭, 武振汝, 卢徐锋, 等. 肝细胞肝癌中HDAC3的表达及临床意义[J]. 世界华人消化杂志, 2017, 25(10): 922-928. DOI: 10.11569/wcjd.v25.i10.922. doi:10.11569/wcjd.v25.i10.922
[12]	Ji H, Zhou Y, Zhuang X, et al. HDAC3 deficiency promotes liver cancer through a defect in H3K9ac/H3K9me3 transition[J]. Cancer Res, 2019, 79(14): 3676-3688. DOI: 10.1158/0008-5472.CAN-18-3767. doi:10.1158/0008-5472.CAN-18-3767pmid:31097476
[13]	Boege Y, Malehmir M, Healy ME, et al. A dual role of caspase-8 in triggering and sensing proliferation-associated DNA damage, a key determinant of liver cancer development[J]. Cancer Cell, 2017, 32(3): 342-359.e10. DOI: 10.1016/j.ccell.2017.08.010. doi:S1535-6108(17)30354-9pmid:28898696
[14]	Mo J, Liang H, Su C, et al. DDX3X: structure, physiologic functions and cancer[J]. Mol Cancer, 2021, 20(1): 38. DOI: 10.1186/s12943-021-01325-7. doi:10.1186/s12943-021-01325-7pmid:33627125
[15]	Chan CH, Chen CM, Lee YW, et al. DNA damage, liver injury, and tumorigenesis: consequences of DDX3X loss[J]. Mol Cancer Res, 2019, 17(2): 555-566. DOI: 10.1158/1541-7786.MCR-18-0551. doi:10.1158/1541-7786.MCR-18-0551
[16]	Shen J, Chen M, Lee D, et al. Histone chaperone FACT complex mediates oxidative stress response to promote liver cancer progression[J]. Gut, 2020, 69(2): 329-342. DOI: 10.1136/gutjnl-2019-318668. doi:10.1136/gutjnl-2019-318668pmid:31439637
[17]	Goldstein M, Kastan MB. The DNA damage response: implications for tumor responses to radiation and chemotherapy[J]. Annu Rev Med, 2015, 66: 129-143. DOI: 10.1146/annurev-med-081313-121208. doi:10.1146/annurev-med-081313-121208pmid:25423595
[18]	Chen CC, Chen CY, Cheng SF, et al. Hydroxygenkwanin increases the sensitivity of liver cancer cells to chemotherapy by inhibiting DNA damage response in mouse xenograft models[J]. Int J Mol Sci, 2021, 22(18): 9766. DOI: 10.3390/ijms22189766. doi:10.3390/ijms22189766
[19]	Herath NI, Devun F, Herbette A, et al. Potentiation of doxorubicin efficacy in hepatocellular carcinoma by the DNA repair inhibitor DT01 in preclinical models[J]. Eur Radiol, 2017, 27(10): 4435-4444. DOI: 10.1007/s00330-017-4792-1. doi:10.1007/s00330-017-4792-1pmid:28374075
[20]	Chen CC, Chen CY, Ueng SH, et al. Corylin increases the sensitivity of hepatocellular carcinoma cells to chemotherapy through long noncoding RNA RAD51-AS1-mediated inhibition of DNA repair[J]. Cell Death Dis, 2018, 9(5): 543. DOI: 10.1038/s41419-018-0575-0. doi:10.1038/s41419-018-0575-0
[21]	Wang C, Tang H, Geng A, et al. Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors[J]. Proc Natl Acad Sci U S A, 2020, 117(42): 26356-26365. DOI: 10.1073/pnas.2002917117. doi:10.1073/pnas.2002917117pmid:33020270
[22]	Cherng YG, Chu YC, Yadav VK, et al. Induced mitochondrial alteration and DNA damage via IFNGR-JAK2-STAT1-PARP1 pathway facilitates viral hepatitis associated hepatocellular carcinoma aggressiveness and stemness[J]. Cancers (Basel), 2021, 13(11): 2755. DOI: 10.3390/cancers13112755. doi:10.3390/cancers13112755
[23]	周蔚文, 孙晓南. 肝外胆管癌放疗的研究进展[J]. 国际肿瘤学杂志, 2020, 47(7): 431-435. DOI: 10.3760/cma.j.cn371439-20200224-00051. doi:10.3760/cma.j.cn371439-20200224-00051
[24]	Sheng H, Huang Y, Xiao Y, et al. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma[J]. J Immunother Cancer, 2020, 8(1): e000340. DOI: 10.1136/jitc-2019-000340. doi:10.1136/jitc-2019-000340
[25]	Xie Y, Liu C, Zhang Y, et al. PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair[J]. PLoS One, 2021, 16(10): e0258817. DOI: 10.1371/journal.pone.0258817. doi:10.1371/journal.pone.0258817
[26]	Gerossier L, Dubois A, Paturel A, et al. PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles' heel?[J]. Clin Res Hepatol Gastroenterol, 2021, 45(5): 101553. DOI: 10.1016/j.clinre.2020.09.014. doi:10.1016/j.clinre.2020.09.014
[27]	Chen Y, Wang X, Deng X, et al. DNA damage repair status predicts opposite clinical prognosis immunotherapy and non-immunotherapy in hepatocellular carcinoma[J]. Front Immunol, 2021, 12: 676922. DOI: 10.3389/fimmu.2021.676922. doi:10.3389/fimmu.2021.676922
[28]	李华兰. XPC、ERCC1及XPF表达与肝细胞癌临床病理特征及预后的相关性研究[D]. 南宁: 广西医科大学, 2019. DOI: 10.27038/d.cnki.ggxyu.2019.000139. doi:10.27038/d.cnki.ggxyu.2019.000139
[29]	Liao X, Li Y, Li H, et al. Expression and clinical significance of ERCC1 and XPF in human hepatocellular carcinoma[J]. Onco Targets Ther, 2020, 13: 1059-1072. DOI: 10.2147/OTT.S237916. doi:10.2147/OTT.S237916
[30]	Chen X, Legrand AJ, Cunniffe S, et al. Interplay between base excision repair protein XRCC1 and ALDH2 predicts overall survival in lung and liver cancer patients[J]. Cell Oncol (Dordr), 2018, 41(5): 527-539. DOI: 10.1007/s13402-018-0390-8. doi:10.1007/s13402-018-0390-8

Research progress on the relationship between DNA damage repair genes and liver cancer

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References30

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[6]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197.
[7]	Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209.
[8]	Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222.
[9]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[10]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[11]	Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185.
[12]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[13]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[14]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[15]	Huang Zhen, Chen Yongshun.Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2024, 51(1): 59-64.